skip to content
Primary navigation


Drug - Fasenra™ (benralizumab) [AstraZeneca Pharmaceuticals LP.]

July 2018

Therapeutic area - Asthma

Initial approval criteria

  • Patient must be 12 years of age or older AND
  • Has a diagnosis of  severe eosinophilic asthma with a documented blood eosinophiol count of either:
    • ≥150 cells/microliter at baseline or ≥ 300 cells/microliter in the past 12 months as documented in chart notes and
  • Patient’s symptoms are not well controlled despite a 3 month adherent trial of high-dose inhaled corticosteroids in combination with a long-acting bronchodilator or leukotriene modifier AND 
  • Patient has had 2 or more exacerbations requiring treatment with systemic corticosteroids in the past 12 months AND
  • Fasenra must be used as an add-on to BOTH high-dose inhaled corticosteroids AND an additional controller medication (e.g., long-acting beta-agonist, etc.) AND
  • Patient must not have concurrent use of Xolair, Nucala or Cinqair AND
  • At time of request, provide baseline FEV1 and frequency of asthma exacerbation per month
  • Initial approval will be for 6 months in duration

Renewal approval criteria

  • Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following:
    • Parasitic (helminth) infection
    • Herpes zoster infection
  • Treatment has resulted in clinical improvement as documented by at least ONE of the following:
    • Decreased frequency of exacerbations (defined as improvement of asthma as demonstrated by decreased use of oral/systemic corticosteroids and/or less frequent hospitalizations and/or reduced frequency of ER visits)
    • Improvement in lung function, measured in FEV1
  • Renewal approval will be for 12 months in duration

Quantity Limits

  • Five injections (30mg/mL prefilled syringe) for the first 6 months
  • Six injections (30mg/mL prefilled syringe) for subsequent 12 months

Billing of Fasenra

Fasenra is not covered through the MHCP fee-for-service pharmacy benefit and must be submitted as a medical claim. Fasenra should be administered by a healthcare professional in a healthcare setting. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended by the manufacturer.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top